RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.

@article{Pogam2010RG7128AO,
  title={RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.},
  author={Sophie Le Pogam and Amritha Seshaadri and Aren Ewing and Hyunsoon Kang and Alan Kosaka and Jun-mei Yan and M. Michelle Berrey and Bill Symonds and Abel De La Rosa and Nick Cammack and Isabel N{\'a}jera},
  journal={The Journal of infectious diseases},
  year={2010},
  volume={202 10},
  pages={
          1510-9
        }
}
INTRODUCTION RG7128 (prodrug of PSI-6130) shows potent antiviral efficacy in patients infected with hepatitis C virus (HCV) genotypes 1, 2, or 3, with mean viral load decreases of 2.7 and 5 log(10) IU/mL, respectively, associated with 1500-mg doses twice daily after monotherapy for 2 weeks and with 1000-mg and 1500-mg doses twice daily after treatment in combination with the standard of care (SOC) for 4 weeks. RESULTS From 32 patients treated with RG7128 monotherapy for 2 weeks, marginal… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 48 CITATIONS

Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis

Edward Gane, Regine Rouzier, +10 authors James Thommes
  • Hepatology International
  • 2016
VIEW 1 EXCERPT
CITES METHODS